If you are viewing this page, it is highly likely that you or somebody you care about is struggling with the rebound congestion associated with Afrin addiction or other decongestant nasal spray addiction. It is likely that the problem has persisted for an extended period of time despite repeated attempts to withdraw. You have been searching for information and help in finally overcoming the problem.
This page is designed to be a comprehensive source of information for anyone struggling with decongestant induced rebound congestion (rhinitis medicamentosa).
Rhinostat understands the complex problem of rhinitis medicamentosa and the impact it has on the quality of a person's life. We have developed and patented an apparatus and a method which is designed to wean people from Afrin and other nasal sprays in a gradual and comfortable manner which maintains normal nasal airflow as the compound is withdrawn and the rebound congestion is abated. This is what sets Rhinostat apart from other treatment protocols, which generally involve a 4-7 day period of complete congestion and extreme discomfort. Only those people who have been addicted themselves can understand the impact of this problem.
Rhinostat is the rhinitis medicamentosa company. If you are looking for answers and help in finally ending your nasal spray addiction, please read this informative page. Other medical research and literature can be found on our web site as well.
This page is bookmarked and divided into the following sections:
Rhinitis Medicamentosa (nasal spray addiction as a result of rebound congestion) is caused by the prolonged use of Afrin and other over-the-counter decongestant nasal sprays. The active ingredient in these sprays is a topical vasoconstrictor that temporarily reduces the size of the nasal turbinates, opens the nasal airway and provides decongestant relief from the rebound congestion.
When the decongestants are used for more than 3 consecutive days, it provokes a condition known as rebound congestion
Rebound congestion is the result of abnormal swelling and enlargement (hypertrophy) of the nasal mucosa, which blocks the nasal airway completely and causes extreme discomfort. This rebound congestion is temporarily relieved once again by the administration of another dose of Afrin or other nasal spray.
As soon as the temporary effect of the last dose of spray wears off, the swollen nasal mucosa again block the airway and another dose of spray is required to provide relief. The commencement of this cycle represents the initiation of the addiction.
Afrin nasal spray addiction can (and often does) last a lifetime. Rhinostat has documented many cases of individuals who reported that they have been addicted to Afrin and other nasal sprays for more than forty years.
Because the nasal spray itself is the root cause of the problem, the only effective way to eliminate it is to discontinue the use of the sprays.
As any person that has suffered with rhinitis medicamentosa will tell you, this is much easier said than done. Breaking this addiction is not simply a matter of will power. The ability to breathe comfortably is essential to normal human functionality.
Only a small percentage of these people (less than 4%, according to our research) are able to endure the misery associated with "cold turkey" withdrawal. Unable to sleep, eat, work or socialize comfortably, the large majority of these people simply return to the use of the spray to end their misery.
It is not uncommon for these people to keep their problem a secret from their families, co-workers, friends and even their physicians. They excuse themselves from social settings, wake up in the middle of the night and learn how to integrate the use of the sprays into their daily routines, in solitude.
They keep a bottle of Afrin in their pocket or purse, their nightstand, glove box, backpack, attachι case and anywhere else necessary to ensure that it is readily available when needed.
Addicted persons often stock up, plan ahead and buy in volume (when on sale.) They know every retail store in their neighborhood that carries the product. Some may even rotate the places they go to purchase it, so as not to reveal their addiction to sales clerks. They often purchase other items along with the sprays to draw attention away from the item.
They may not be experts in chemistry, but they know the name of the active ingredient in their particular spray. Oxymetazoline, Phenylepherine or Xylometazoline. Regardless of the specific brand, they always select a spray with the correct compound. Unless they have a very sympathetic and supportive spouse or partner, they buy their own sprays.
The prospect of things such as surgical anesthesia, a camping trip to an isolated location or an ocean cruise (where they have no easy and immediate access to the nasal sprays) is a nightmare.
Many of these people tell us that nasal spray
addiction is the most miserable and frustrating problem they have ever
dealt with. This entire physiologic and psychological phenomenon is something that Rhinostat is
intimately familiar with and it remains the subject of our focused
In search of an answer, many of these patients turn to their physicians for help in ending nasal spray addiction.
Rhinitis Medicamentosa is a very frustrating problem for physicians to effectively treat. There are no FDA approved drugs nor therapies specifically for the treatment of RM patients. Most commonly, these patients are given a course of intranasal and/or systemic steroids and are told to discontinue their use of the decongestants. In some cases, surgery to reduce the turbinates or to correct a deviated septum is performed.
Regardless of what treatment is prescribed, the cornerstone of the therapy is always the same. Patients must discontinue their use of the sprays. It is this aspect of the treatment that presents the problem for these patients.
In spite of the large patient population (estimated to be more than 10 million in America alone) very little clinical research has been done on rhinitis medicamentosa. The most extensive and comprehensive research that exists was done by Drs. Graf, Hallen, Enerdal and Juto at the renowned Karolinska Institute in Stockholm, Sweden.
The use of the steroid nasal sprays in treating rhinitis medicamentosa was studied by Drs. Graf, Hallen, Enerdal and Juto in 1997. Their landmark study published in the Journal of Clinical and Experimental Allergy forms the basis of the use of steroid nasal sprays in treating rhinitis medicamentosa. A copy of this study is available on our medical research page.
From the perspective of the rhinitis medicamentosa patient, the single most important aspect of treatment is the ability to continue to move air (breathe) during the withdrawal process. The 1997 RM study (View It) concluded that the use of the steroid nasal sprays offered no improvement in air movement when compared to placebo.
In other words, substituting the nasal steroids for the decongestant offers no more relief than quitting cold turkey, in terms of your ability to breathe.
The conclusions reached in the study are in full accordance with the research we have done at Rhinostat.
Patients who have allergic rhinitis in addition to having rhinitis medicamentosa, should work with their health care providers to suppress the allergic symptoms and this treatment will often include steroids. Rhinostat is frequently used in conjunction with nasal steroids as a combination therapy.
If you have any kind of medical or physiologic condition contributing to your congestion (in addition to rhinitis medicamentosa) it is necessary that it be treated effectively either before or during your attempt to withdraw from the decongestant sprays. Such conditions may include a deviated septum, among many other things.
If, however, you are not allergic, have no other medical or physiologic conditions and are simply addicted to the decongestants (78% of patients according to our research) there may be no harm in using the steroids along with Rhinostat, but no essential benefit, in terms of nasal airflow.
In our opinion, physicians would benefit greatly from two very important things which would help them in treating RM patients as well as understanding why it is so difficult for patients to simply exercise their will power and simply stop.
First, if you can find a doctor who has suffered from nasal spray addiction personally (we meet hundreds of them) it can make a big difference. There are many unique and severe aspects of this problem that some physicians may not fully appreciate. Of course, this is not always necessary or practical.
Second (and more importantly) there is an instrument called a
can be used to accurately measure nasal inspiratory flow. If your
doctor had one of these instruments, he or she could quantify how well
you are (or are not) breathing through your nose and evaluate the efficacy
(or inefficacy) of the treatment they prescribe for you.
Although these instruments are essential for measuring nasal flow rates and pressures very few physician's offices are equipped with them. RM patients already have their own physiologic internal rhinomanometers. As soon as they sense the onset of rebound congestion, they reach for their bottle and suppress it.
Rhinostat relies exclusively on rhinomanometry to validate its method. With rhinomanometry, we can see that patients who are weaning themselves gradually (using the Rhinostat System) maintain normal nasal inspiratory flow, compared to patients who are treated with other methods and are unable to move any air for the first 4-7 days.
It is generally accepted within the physician community that rhinitis medicamentosa patients must endure a 4-7 day period of complete congestion before their prescribed treatments take effect. Rhinostat believes that this period of suffering, misery, sleep deprivation and anxiety is entirely unnecessary.
What physicians do not fully appreciate is that rhinitis medicamentosa patients are rarely able to endure 4-7 hours, much less 4-7 days of complete nasal airway blockage. If these patients were able to endure such severe discomfort for that long, they would have already ended their own addictions without seeking medical assistance.
Rhinitis Medicamentosa patients turn to their health care providers in the hope that they will be able to offer them a way to end their use of the sprays without this 4-7 day period of misery. Rhinomanometry validates the proposal that to date, only a gradual reduction protocol (Rhinostat) will achieve this objective on a consistent basis.
Using Rhinostat, rhinitis medicamentosa patients reduce their dosage strength each day via serial dilution. The targeted rate of reduction is 15% per day. RM patients need decongestant relief on demand throughout the withdrawal process and Rhinostat allows them to administer the needed dose as they continue to make progress each day.
The length of time it takes to withdraw using Rhinostat ranges between 17 and 42 days, according to user reports to date. The average number of days is 27.
RM patients are a highly motivated group. They derive no pleasure from using nasal decongestants. Rhinostat users spend a few minutes each day "cycling" their Rhinostat kits. Their strong desire to rid themselves of their nasal spray addiction motivates them to comply and succeed.
Ending nasal spray addiction is often reported to be the most significant quality of life issue facing these people. Rhinostat has received hundreds of warm letters and testimonials from people who tried many times and never thought they could end their dependence.
In the patient group that is non-allergic and that has no other underlying medical or physiologic causes of the congestion, Rhinostat has very high patient compliance and success rates.
Among patients who do have allergies, a deviated septum or some other underlying medical or physiologic problem, the success rate using Rhinostat will be highly dependant upon the treatment outcome of the other underlying disorder.
Patients with these other contributory causes are unable to distinguish between rebound congestion caused by rhinitis medicamentosa and the congestion caused by the other factors. They know that they are unable to breathe and that the continued use of the sprays provides the relief they need. When other problems are present, withdrawal from the sprays alone will not provide complete relief and the return to the use of the sprays is inevitable, unless the other underlying causes are eliminated as well.
Many patients are not aware of other underlying problems which may be present. If Rhinostat's gradual reduction method does not succeed in ending the addiction, it is generally a sign that there is another contributing factor. If Rhinostat is unable to end a patient's addiction for any reason, patients may return their kits to Rhinostat for a full refund of the purchase price, or request a second kit for another attempt.
Occasionally, an additional Rhinostat Kit is needed for a
second attempt. One example of why this may be necessary is if a
person catches a common cold during the withdrawal process and needs to
start over. Rhinostat's policy is to provide the additional kit -
free of charge.
|Rhinostat Home||Order Rhinostat||Testimonials & Success Stories|
|Frequently Asked Questions||About Rebound Congestion||View Rhinostat PowerPoint|
|How Rhinostat Works||Related Links||Medical Articles|
Rhinostat Systems, LLC
The Rhinitis Medicamentosa (Rebound Congestion) Company
Toll Free: (877) RHINOSTAT (877) 744-6678